Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 381874, 6 pages
Research Article

Expression and Significance of MicroRNA-183 in Hepatocellular Carcinoma

1Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China
2Key Laboratory of Artificial Cell, Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin 300170, China
3Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin 300170, China

Received 2 August 2013; Accepted 19 September 2013

Academic Editors: A. Alaiya, E. Briasoulis, and A. Percesepe

Copyright © 2013 Zenghui Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. In our previous study, we found that some miRNAs were deregulated in hepatocellular carcinoma (HCC), including miR-183. However, the expression of miR-183 in the progression of benign liver diseases to HCC and its correlation with clinicopathologic factors remain undefined. Methods. MiR-183 expression was measured in normal controls (NC) ( ), chronic viral hepatitis B or C (CH) tissues ( ), liver cirrhosis (LC) tissues ( ), HCC tissues ( ), and adjacent nontumor tissues (NT) ( ) by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). Results. The expression levels of miR-183 were significantly higher in HCC than in NT, LC, CH, and NL ( , , , , resp.). The upregulated miR-183 in HCC was correlated with TNM stage ( ) and cirrhosis ( ). The Kaplan-Meier survival analysis showed that miR-183 expression was not associated with the survival of HCC patients. However, miR-183 yielded an area under the curve (AUC) of 0.808 with 59.8% sensitivity and 91.8% specificity in discriminating HCC from benign liver diseases (CH and LC) or NC. Conclusions. The upregulated miR-183 may associate with onset and progression of HCC, but not with the patient survival. A further research is needed to determine the potential of miR-183 as biomarker for HCC.